Enovis Completes Dr. Comfort Footcare Solutions Sale for Up to $60 Million
ByAinvest
Wednesday, Oct 8, 2025 8:16 am ET1min read
ENOV--
The sale represents a strategic move for Enovis, allowing the company to focus on its core strengths and market leadership in the Prevention & Recovery franchise. Damien McDonald, Enovis' Chief Executive Officer, stated that the transaction will enable Enovis to expand margins, enhance profitability, and accelerate debt reduction, further strengthening its role as a focused medical technology innovator [1][2].
Enovis will provide additional strategic commentary on the transaction during its third quarter results call on November 6, 2025, at 8:30 am ET. Investors can access the live webcast via a link on the Enovis website [1][2].
Promus Equity Partners, a multi-family asset management firm based in Chicago with approximately $2.7 billion under management, will be acquiring the Dr. Comfort business. The firm is excited to build upon the long heritage of Dr. Comfort in serving clinicians, channel partners, and patients with quality products and exceptional service [1][2].
Enovis is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The company’s shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV [1][2].
Enovis has completed the sale of its Dr. Comfort Footcare Solutions business to Promus Equity Partners for up to $60 million. The deal includes an upfront payment of $45 million and up to $15 million payable upon certain milestones. Enovis CEO Damien McDonald stated that the sale sharpens the company's focus on core strengths and positions it to expand margins, enhance profitability, and accelerate debt reduction.
Enovis (NYSE: ENOV) has completed the sale of its Dr. Comfort Footcare Solutions business to Promus Equity Partners for up to $60 million. The deal includes an upfront payment of $45 million and up to $15 million payable upon the achievement of certain milestones [1][2].The sale represents a strategic move for Enovis, allowing the company to focus on its core strengths and market leadership in the Prevention & Recovery franchise. Damien McDonald, Enovis' Chief Executive Officer, stated that the transaction will enable Enovis to expand margins, enhance profitability, and accelerate debt reduction, further strengthening its role as a focused medical technology innovator [1][2].
Enovis will provide additional strategic commentary on the transaction during its third quarter results call on November 6, 2025, at 8:30 am ET. Investors can access the live webcast via a link on the Enovis website [1][2].
Promus Equity Partners, a multi-family asset management firm based in Chicago with approximately $2.7 billion under management, will be acquiring the Dr. Comfort business. The firm is excited to build upon the long heritage of Dr. Comfort in serving clinicians, channel partners, and patients with quality products and exceptional service [1][2].
Enovis is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The company’s shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV [1][2].

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet